NHS England is planning a phased rollout of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), following promising results in clinical trials. The drug has been recommended for patients with obesity at a cost of $159.6 per month for the highest dose. Initially, the rollout plans to reach up to 240,000 people and will trial various cost-effective delivery models, prioritising patients with a BMI above 40 and three or more weight-related conditions.
Life-Saving Tech at Risk: How to Safeguard Medical Devices from Cyber Threats
The rise of digital medical devices has improved healthcare outcomes but also increased vulnerability to cyberattacks. The devices, critical to a connected healthcare ecosystem, can
